Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. HDL cholesterol and non-cardiovascular disease: a narrative review

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. The Role of Leptin in Fetal Growth during Pre-Eclampsia

    Publikation: Bidrag til tidsskriftReviewpeer review

  3. A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ciclosporin

    Publikation: Bog/antologi/afhandling/rapportRapportRådgivning

  4. The Adaptive COVID-19 Treatment Trial-1 (ACTT-1) in a real-world population: a comparative observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Psoriasis is a chronic immune-mediated inflammatory disease affecting women of childbearing potential. Biologic agents, notably Tumor Necrosis Factor inhibitors (TNFi), are the only current non-contraindicated systemic treatment option during pregnancy. TNFi comprised of complete immunoglobulin G (IgG) antibodies antibodies (adalimumab, golimumab, and infliximab) actively cross the placenta from the second trimester and are detectable in the child up to one year postpartum. Data on safety of TNFi are conflicting; however a trend towards drug-specific harm has been reported, with increased risk of congenital malformations and preterm birth. TNFi exposure may alter the immune system of the infant towards hypersensitivity and reduced response to intracellular infections. Confounding by indication should be considered, as chronic inflammatory disease itself may pose a risk of adverse pregnancy outcomes. The quality of the current evidence is very low and no studies specifically address TNFi safety in women with psoriasis. Nonetheless, risks associated with TNFi treatment must be balanced against the as-yet uncertain risk of adverse outcomes in infants born to women with severe psoriasis. We searched PubMed using Medical Subject Headings (MeSH) terms and identified relevant studies and guidelines. Herein, we present the current knowledge of the use and safety of TNFi during pregnancy in women with psoriasis.

OriginalsprogEngelsk
TidsskriftInternational Journal of Molecular Sciences
Vol/bind19
Udgave nummer5
ISSN1661-6596
DOI
StatusUdgivet - 3 maj 2018

ID: 55741536